Vivoryon Therapeutics N.V.

Equities

VVY

NL00150002Q7

Biotechnology & Medical Research

Market Closed - Euronext Amsterdam Other stock markets 11:35:27 2024-04-26 am EDT			5-day change	1st Jan Change
0.8 ^EUR	-2.44%		+76.60%	-90.17%

Apr. 24	Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024
Mar. 15	Vivoryon Therapeutics N.V Announces Resignation of Board of Directors	CI

Vivoryon Therapeutics N : Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease

March 04, 2024 at 03:36 am EST

Vivoryon Therapeutics N.V.

Vivoryon Therapeutics N.V.

Below you will find information from the register publication of inside information. The information has been provided by the organisation.

Registration date04 mar 2024 - 07:08

Statutory nameVivoryon Therapeutics N.V.

TitleVivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer's Disease

Previous result

Next result

Related downloads

202403040000000001_VVY_2024-03-04_VIVIAD Data Release.pdf(opens in a new window)

Date last update: 04 March 2024

Attachments

Original Link
Permalink

Disclaimer

Vivoryon Therapeutics NV published this content on 04 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 March 2024 08:36:09 UTC.

Latest news about Vivoryon Therapeutics N.V.

Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024	Apr. 24
Vivoryon Therapeutics N.V Announces Resignation of Board of Directors	Mar. 15	CI
Vivoryon Therapeutics N.V. Provides Update on Viviad Phase 2B Study of Varoglutamstat in Early Alzheimer?S Disease	Mar. 04	CI
Transcript : Vivoryon Therapeutics N.V., Q3 2023 Earnings Call, Dec 06, 2023	Dec. 06
Vivoryon Therapeutics N.V. Announces Executive Changes	Dec. 06	CI
Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision	23-10-26	CI
Transcript : Vivoryon Therapeutics N.V. - Special Call	23-10-17
Vivoryon Therapeutics N.V. Announces Board Appointments	23-09-15	CI
Transcript : Vivoryon Therapeutics N.V., H1 2023 Earnings Call, Sep 07, 2023	23-09-07
Vivoryon Therapeutics N.V. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-07	CI
Certain Shares of Vivoryon Therapeutics N.V. are subject to a Lock-Up Agreement Ending on 24-AUG-2023.	23-08-23	CI
Vivoryon Therapeutics Promotes Chief Medical Officer to CEO	23-08-07	MT
Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimerâ€™s Disease	23-07-16	CI
Vivoryon Therapeutics N.V. Approves Board Appointments	23-06-21	CI
Vivoryon Therapeutics CEO to Step Down in FY24	23-06-16	MT
Vivoryon Therapeutics N.V. Announces Resignation of Ulrich Dauer as CEO	23-06-15	CI
Vivoryon Rises 7% on EUR25 Million Capital Raise	23-05-26	MT
Vivoryon Therapeutics N.V. Announces Resignation of Dinnies Johannes Von Der Osten, PhD, and Jörg Neermann, PhD from the Board of Directors	23-05-01	CI
Transcript : Vivoryon Therapeutics N.V., Q4 2022 Earnings Call, Apr 19, 2023	23-04-19
Vivoryon Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-19	CI
Vivoryon Therapeutics N.V. Auditor Raises 'Going Concern' Doubt	23-04-18	CI
Vivoryon Therapeutics N.V. Provides Progress Update on Varoglutamstat Clinical Development for the Treatment of Alzheimer's Disease	23-03-28	CI
Transcript : Vivoryon Therapeutics N.V. Presents at Barclays Global Healthcare Conference, Mar-16-2023 08:00 AM	23-03-16
Transcript : Vivoryon Therapeutics N.V., Q3 2022 Earnings Call, Nov 22, 2022	22-11-22
Transcript : Vivoryon Therapeutics N.V., H1 2022 Earnings Call, Sep 30, 2022	22-09-30

Chart Vivoryon Therapeutics N.V.

Duration

Period

More charts

Company Profile

Vivoryon Therapeutics N.V. specializes in the research and development of therapeutic products for the treatment of Alzheimer disease. At the end of 2022, the group has a portfolio of a product in phase II clinical development (Varoglutamstat; PQ912) and 2 products in the preclinical development phase.

Sector

Biotechnology & Medical Research

Calendar

2024-06-11 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.8 EUR

Average target price

41.57 EUR

Spread / Average Target

+5,095.83%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VIVORYON THERAPEUTICS N.V.	-90.17%	22.26M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research